Anti-CD3 antibodies are immunosuppressants. They work by reducing the amount of effector T cells and triggering the formation of Tregs that are adaptive, but the mechanism that drives this action isn't completely comprehended. You can know more about anti-CD3 epsilon/Cd3e antibody picoband online.
Image Source: Google
Muromonab, a CD3 mAb (a mouse mAb that binds to the human CD3) has been approved to stop renal allograft rejection. However, one of the most significant side effects could be the CRS (cytokine release syndrome).
The first anti-CD3 antibody that was to be approved for the treatment of human diseases is muromonab CD3 (OKT3) at the time of 1986, in order to treat rejection of transplants. However, the creation of OKT3 and other monoclonal anti-CD3 antibodies was slowed by severe adverse reactions triggered by the cytokine-related storm, which is a result of widespread T-cell activation.
Humanized non-mitogenic anti-CD3 antibodies that are glycosylated like otelixizumab have shown promising results in patients recently diagnosed with Type 1 Diabetes.
This has prompted renewed interest in these antibodies for the treatment of auto-immune diseases 77RThe results of these antibodies are promising for the treatment of autoimmune diseases.
Newer monoclonal antibody types with similar mechanisms of action are teplizumab as well as visilizumab. These are being evaluated in various ailments, like ulcerative colitis, Crohn's disease or type I diabetes as well as for promoting immune tolerance.
Studies in Phase III will evaluate the potential risks of long-term complications and further establish the role of otelixizumab during the treatment of diabetes.